Core Viewpoint - 康希诺生物 has announced a restricted stock incentive plan for 2025, aiming to grant 2.58 million shares, which represents approximately 1.04% of the company's total share capital at the time of the announcement [1] Summary by Sections - **Incentive Plan Details** - The plan includes an initial grant of 2.0655 million shares to 87 recipients [1] - The grant price, including reserves, is set at 41.20 yuan per share [1]

恒生指数冲高回落，截止目前恒生指数下跌1.08%。其中恒生科技跌幅居前，恒生工商、国指ESG等紧 随其后；内房地、内石油。公用等逆势小涨。 恒生工商低开低走，截至目前下跌1.33%，其中携程集团下跌2.01%，中国生物制药、紫金矿业、信义 光能、安踏体育、网易、周大福等今20只个股跌幅在1%上方。 内房地探底回升，盘中一度下跌1.36%，截至目前微跌0.02%。其中万物云下跌0.92%，九龙仓集团、建 发国际、贝壳、华润万象生活等股均小幅下跌；越秀地产、海外发展、华润置地等股均小幅上涨。 内容只是个人观点，仅供参考，不作为投资依据！欢迎关注交流，互相学习、共同探讨！ 恒生科技大幅低开后冲高回落，截止目前下跌1.21%，其中地平线机器人大跌5.75%，小米集团下跌 4.79%，金山软件下跌4.26%，金蝶国际下跌3.68%，京东健康、阿里健康、京东集团等超10只个股跌幅 均在2%上方。 ...

Core Viewpoint - The company, Bory Pharmaceutical, plans to issue H-shares and list on the Hong Kong Stock Exchange to accelerate its international strategy and enhance its capital strength and competitiveness [1][2] Group 1: H-Share Issuance - The H-share issuance will combine public offerings in Hong Kong and international placements targeting qualified international institutional investors [1] - The raised funds will primarily support R&D for pipeline products, expand production capacity, strategic investments and acquisitions, and supplement working capital [1] Group 2: Market Positioning - Bory Pharmaceutical aims to leverage its differentiated approach in the competitive GLP-1 sector through "dual-target + combination therapy" strategies [1] - The product BGM0504 injection shows superior clinical data compared to Semaglutide, while BGM1812 addresses the niche market of "hidden obesity" [1] - The comprehensive and differentiated product pipeline is expected to attract international investors in the Hong Kong market [1] Group 3: Future Growth Potential - The controlling shareholder proposed a buyback of A-shares to bind the core team with the company's interests through stock incentive plans [2] - The move to list in Hong Kong reflects a trend among innovative pharmaceutical companies to accelerate global expansion via overseas capital markets [2] - With multiple clinical data readouts expected by 2026 and the validation of oral formulation technology, the company is positioned to play a significant role in the global metabolic disease treatment market [2]

Core Viewpoint - The company has decided to repurchase and cancel a total of 220,300 restricted stocks due to the departure of certain incentive plan participants and performance evaluations not meeting the required standards [2][3][4]. Summary by Sections Repurchase and Cancellation Reasons - The repurchase is based on the departure of 10 participants from the 2022 incentive plan and 3 from the 2024 plan, leading to the cancellation of their stock options [2][3]. - A total of 241,300 restricted stocks were approved for repurchase, with 220,300 stocks actually being canceled due to one participant's stocks being frozen by the court [2][3]. Repurchase Details - The repurchase includes 168,700 stocks from the 2022 plan and 72,000 stocks from the 2024 plan, with repurchase prices set at 15.65 yuan and 18.09 yuan per stock respectively [3][4]. - The company has established a dedicated securities account for the repurchase process and expects the cancellation to be completed by October 9, 2025 [5]. Impact on Share Structure - After the cancellation, the remaining restricted stocks will total 6,382,480, and the repurchase will not affect the control of the company or its compliance with listing conditions [5][6]. Compliance and Legal Opinions - The board has confirmed that the decision-making process and disclosures comply with relevant regulations and that there are no violations of the rights of the incentive participants or creditors [7][8]. - Legal counsel has affirmed that the repurchase has received necessary approvals and adheres to applicable laws and regulations [8].

Core Viewpoint - The launch of China's first domestically developed nine-valent HPV vaccine in Zhejiang marks a significant advancement in cervical cancer prevention, providing a more affordable option for women aged 9 to 45 [2][4]. Group 1: Vaccine Details - The vaccine is priced at 499 yuan per dose, which is only 40% of the cost of imported counterparts, significantly lowering the barrier for vaccination [2]. - The vaccine utilizes an advanced E. coli expression system, breaking international monopolies and making China the second country capable of independently supplying high-priced HPV vaccines [2]. - Clinical studies published in The Lancet Infectious Diseases confirm that the vaccine's immune response and safety are comparable to imported vaccines, with a 100% protection rate against persistent infections caused by HPV types 52 and 58, which are prevalent among Asian women [2]. Group 2: Vaccination Program - The vaccination schedule has been optimized: a two-dose regimen for females aged 9-17 and a three-dose regimen for those aged 18-45 [3]. - Experts emphasize that while vaccination is crucial, regular HPV testing and TCT screenings are necessary for comprehensive prevention, highlighting the importance of a "vaccine + screening" approach [3]. Group 3: Community Support and Initiatives - Wantai Biological Pharmacy announced a donation of 6,000 doses of bivalent HPV vaccines to the Zhejiang Cancer Foundation to support public welfare activities, particularly for sanitation workers and migrant workers [3]. - The Zhejiang Cancer Foundation has been active for ten years in providing medical assistance and promoting early detection and treatment of cancer, aiming to spread cancer prevention knowledge throughout the province [3]. Group 4: Future Plans - Starting in October, Zhejiang Province will fully implement the vaccination program for the nine-valent HPV vaccine, aiming to increase vaccination coverage and contribute to the World Health Organization's goal of cervical cancer elimination [4].

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：688336 证券简称：三生国健公告编号：2025-055 三生国健药业（上海）股份有限公司 关于2024年限制性股票激励计划 首次授予部分第一个归属期符合 归属条件的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ● 限制性股票拟归属数量：134.301万股 5、归属安排具体如下： 本次激励计划首次授予的限制性股票的归属安排如下表所示： ■ ● 归属股票来源：公司向激励对象定向发行的公司A股普通股 三生国健药业（上海）股份有限公司（以下简称"公司"）于2025年9月26日召开第五届董事会第十二次 会议，审议通过了《关于2024年限制性股票激励计划首次授予部分第一个归属期符合归属条件的议 案》。公司2024年限制性股票激励计划（以下简称"本次激励计划"）首次授予部分第一个归属期符合归 属条件。现将有关事项说明如下： 一、本次激励计划批准及实施情况 （一）本次激励计划的主要内容 1、股权激励方式：第二类限制性股票。 2、授予数量：根据《三生国健 ...

Core Points - Shanghai Aopumai Biotechnology Co., Ltd. announced that its wholly-owned subsidiary, Shanghai Silun Biotechnology Co., Ltd., successfully passed the EU Qualified Person (QP) audit, receiving a compliance audit report [1][2] - The audit covered various aspects including quality management, production management, facilities, material systems, and packaging and labeling systems, confirming that Silun Biotechnology meets current EU GMP requirements [1] - This achievement establishes a solid foundation for the company's high-quality research and production services in the large molecule biopharmaceutical sector, facilitating further expansion into EU and international markets [2] Company Impact - The successful QP audit indicates that the quality management system of Silun Biotechnology has reached the standards required by EU GMP regulations [2] - The company has developed a comprehensive CDMO service platform for large molecule biopharmaceuticals, providing full-process support from early research to commercial production [1] - The passing of the QP audit is not expected to have a significant impact on the company's current performance [2]

9月24—26日，由药明合联（02268.HK）联合举办的2025 BPD新加坡生物药工艺发展大会圆满落幕。大 会会聚来自欧洲、北美、中国及亚太地区的顶尖生物制药企业与研究机构，通过主题报告、专题研讨等 多种方式，共同探讨行业前沿方向。 药明合联董事长、药明生物首席执行官陈智胜在主题演讲中，深入阐释了智能化工艺、新型原材料应用 等技术突破如何实现成本优化与效率提升，为产业发展提供清晰路径。近年来，生物医药行业迅速发 展，尤其是ADC等复杂疗法正逐步迈入黄金发展期。如何更快更好地推进药物从研发到商业化，是连 接前沿科学与患者生命的桥梁，也是决定创新能否成功产业化的关键。药明合联首席执行官李锦才博士 在致辞中提到，"本次大会旨在促进全球制药企业、生物科技公司、供应商、研究机构等的交流与合 作，推动先进工艺技术在创新药物生产中的应用，惠及全球患者"。 本次大会中，药明合联特设"XDC 创新与发展"（XDC Innovation and Development）专场论坛。论坛邀 请海内外领军企业家、行业专家分享前沿研究成果与产业化实践经验，聚焦技术难点和创新方向，为行 业实现创新化、国际化及高质量发展提供技术指引与路 ...

Group 1 - The company announced a board meeting on September 26, 2025, to propose the adoption of the 2025 A-share incentive plan and the issuance of restricted shares under this plan [1][2] - The company plans to adopt the assessment management measures for the 2025 A-share incentive plan and authorize the board to handle related matters [1][2] - The company will also propose the adoption of the 2025 H-share option plan and authorize the board to manage related matters [1][2] Group 2 - The company intends to grant H-share options to Dr. Xuefeng YU, totaling 371,300 options [2] - The company will propose the cancellation of repurchased A-shares and a reduction in registered capital [1][2]

Group 1 - The company, Changjiang Life Sciences Technology, has announced a transaction involving the issuance of common and preferred shares to acquire 100% equity of Pharmagesic (Holdings) Inc, with specific rights related to cash settlement and buyback options for the preferred shares [1] - The transaction will lead to a business merger with WEX, allowing access to the buyer's extensive experience in biotech fundraising, R&D, and commercialization in the pharmaceutical sector, particularly for pain relief and related diseases [2] - The flagship candidate product, Halneuron®, is expected to advance its clinical trial data and market entry due to the integration of the buyer's expertise and resources [2] Group 2 - The buyer's listing on NASDAQ will facilitate access to the U.S. capital markets, enabling faster R&D for Halneuron® and increasing the company's stake in the buyer to approximately 90% after conversion of preferred shares [3] - Partial waivers of cash settlement and buyback rights for the preferred shares will help the buyer meet NASDAQ shareholder equity requirements while maintaining its listing status [3] - The buyback rights associated with the preferred shares allow the seller to repurchase all Halneuron assets in exchange for cash settlement amounts, ensuring that partial waivers do not affect the seller's rights to repurchase [3]